GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaEngine Inc (ROCO:4162) » Definitions » Institutional Ownership

PharmaEngine (ROCO:4162) Institutional Ownership : 2.99% (As of May. 03, 2025)


View and export this data going back to 2012. Start your Free Trial

What is PharmaEngine Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PharmaEngine's institutional ownership is 2.99%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PharmaEngine's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PharmaEngine's Float Percentage Of Total Shares Outstanding is 0.00%.


PharmaEngine Institutional Ownership Historical Data

The historical data trend for PharmaEngine's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaEngine Institutional Ownership Chart

PharmaEngine Historical Data

The historical data trend for PharmaEngine can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 4.00 4.12 4.17 4.19 4.26 3.31 3.08 2.99 2.99 2.99

PharmaEngine Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


PharmaEngine Business Description

Traded in Other Exchanges
N/A
Address
10 Minsheng East Road, 11th Floor, Section 3, Taipei, TWN, 104
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its projects pipeline are: ONIVYDE was approved by the U.S. FDA, Taiwan FDA, and EMA for patients with gemcitabine-treated metastatic pancreatic cancer; and PEP07. It generates the revenue from Sales of goods.

PharmaEngine Headlines

No Headlines